Zelluna
Description: Zelluna develops off-the-shelf TCR-guided NK cell therapies for solid cancers, leveraging TCRs from long-term cancer survivors.
Country: Norway
Based in: Oslo
Founded: 2016
Funding Stage: Series A/B
Tags: ['Immunotherapy', 'biopharma company', 'cancer']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
